La disciplina delle responsabilità solidali negli appalti e nei subappalti: lo stato dell’arte in continuo movimento (aggiornato al decreto legge 97/2008) = The discipline of joint and several liability in contracts and subcontracting: the state of the art in continuous movement (updated to the law decree 97/2008). WP C.S.D.L.E. "Massimo D'Antona" .IT - 72/2008

N

La disciplina del socio lavoratore tra vera e falsa cooperazione = The discipline of the worker member between true and false cooperation. WP C.S.D.L.E. "Massimo D'Antona" .IT - 61/2007

N

I Riflessi Della Crisi Economica e Della Globalizzazione Sulla Contrattazione Collettiva in Italia

Sommario: 1. La regolazione ed il ruolo della contrattazione collettiva in Italia nei più recenti interventi legislativi e sindacali. – 2. L’Accordo Interconfederale del 28 giugno 2011 e l’art. 8 della l. 14 settembre 2011, n. 148. – 3. Il ruolo della contrattazione collettiva nel decreto legislativo n. 81/2015. – 4. L’Accordo Interconfederale del 9 marzo 2018. – 5. La contrattazione collettiva in Italia tra potere di deroga alla legge e progressivo decentramento

Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis. The ”CANCER DACUS” study

Purpose: We evaluated the role of residual vein thrombosis (RVT) to assess the optimal duration of anticoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs. Patients and Methods: Patients with active cancer and a first episode of DVT treated with low molecular weight heparin (LMWH) for 6 months were eligible. Patients were managed according to RVT findings: those with RVT were randomly assigned to continue LMWH for an additional 6 months (group A1) or to discontinue it (group A2), and patients without RVT stopped LMWH (group B). The primary end point was recurrent venous thromboembolism (VTE) during the 1 year after disconinuation of LMWH, and the secondary end point was major bleeding Analyses are from the time of random assignment. Results: Between October 2005 and April 2010, 347 patients were enrolled. RVT was detected in 242 patients (69. 7%); recurrence occurred in 22 of the 119 patients in group A1compared with 27 of 123 patients in group A2. The adjusted hazard ratio (HR) for group A2 versus A1 was 1. 37 (95% CI, 0. 7 to 2. 5; P =. 311). Three of the 105 patients in group B developed recurrent VTE; adjusted HR for group A1 versus B was 6. 0 (95% CI, 1. 7 to 21. 2; P =. 005). Three major bleeding events occurred in group A1, and two events each occurred in groups A2 and B. The HR for major bleeding in group A1 versus group A2 was 3. 78 (95% CI, 0. 77 to 18. 58; P =. 102). Overall, 42 patients (12. 1%) died during follow-up as a result of cancer progression. Conclusion In patients with cancer with a first DVT, treated for 6 months with LMWH, absence of RVT identifies a population at low risk for recurrent thrombotic events. Continuation of LMWH in patients with RVT up to 1 year did not reduce recurrent VTE

The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry

Background: Venous thromboembolism (VTE) is a major health problem, with over one million events every year in Europe. However, there is a paucity of data on the current management in real life, including factors influencing treatment pathways, patient satisfaction, quality of life (QoL), and utilization of health care resources and the corresponding costs. The PREFER in VTE registry has been designed to address this and to understand medical care and needs as well as potential gaps for improvement. Methods/design: The PREFER in VTE registry was a prospective, observational, multicenter study conducted in seven European countries including Austria, France Germany, Italy, Spain, Switzerland, and the UK to assess the characteristics and the management of patients with VTE, the use of health care resources, and to provide data to estimate the costs for 12 months treatment following a first-time and/or recurrent VTE diagnosed in hospitals or specialized or primary care centers. In addition, existing anticoagulant treatment patterns, patient pathways, clinical outcomes, treatment satisfaction, and health related QoL were documented. The centers were chosen to reflect the care environment in which patients with VTE are managed in each of the participating countries. Patients were eligible to be enrolled into the registry if they were at least 18 years old, had a symptomatic, objectively confirmed first time or recurrent acute VTE defined as either distal or proximal deep vein thrombosis, pulmonary embolism or both. After the baseline visit at the time of the acute VTE event, further follow-up documentations occurred at 1, 3, 6 and 12 months. Follow-up data was collected by either routinely scheduled visits or by telephone calls. Results: Overall, 381 centers participated, which enrolled 3,545 patients during an observational period of 1 year. Conclusion: The PREFER in VTE registry will provide valuable insights into the characteristics of patients with VTE and their acute and mid-term management, as well as into drug utilization and the use of health care resources in acute first-time and/or recurrent VTE across Europe in clinical practice. Trial registration: Registered in DRKS register, ID number: DRKS0000479